Low Concentration Atropine for Myopia Progression in School Children

Chang Gung Medical Foundation

Status: Completed

Conditions: Myopia Progression

Treatments: Drug: Atropine

Study type: Interventional

Funder types: Other

Identifiers

NCT02130167

CMRPG8C0601

Details and patient eligibility

About

Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

Enrollment: 60 patients

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

Exclusion criteria

strabismus, amblyopia. cataract, glaucoma or any ocular diseases ocular surgery history systemic diseases (ex. asthma, heart disease...)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 2 patient groups

0.01% Atropine

Experimental group

Treatment:

Drug: Atropine

0.05% Atropine

Active Comparator group

Treatment:

Drug: Atropine